{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:O32028",
      "entity_text" : "PFS",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ03146",
      "entity_text" : "nivolumab",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "In addition, both nivolumab and pembrolizumab have shown to increase PFS in the adjuvant setting for melanoma.",
  "reading_complete" : "2020-08-04T12:00:25Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T11:58:24Z",
  "trigger" : "increase",
  "evidence" : [ "nivolumab and pembrolizumab have shown to increase PFS" ],
  "pmc_id" : "6174277",
  "score" : 0
}